“SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs”, Mediterr J Hematol Infect Dis, vol. 6, no. 1, p. e2014003, Jan. 2014, doi: 10.4084/mjhid.2014.003.